Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.52 |
| ▸ | BACE1 | P56817 | 11/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ME2 | P23368 | 1/20 | 0.41 |
| ▸ | ME1 | P48163 | 1/20 | 0.41 |
| ▸ | ME3 | Q16798 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646410 | 1.00 | ABCB1 (0.52) | ABCB1BACE1HDAC1LMNAMAPT | |
| SCHEMBL1646680 | 0.96 | ABCB1 (0.49) | ABCB1BACE1HDAC1LMNAMAPT | |
| SCHEMBL15295429 | 0.96 | ABCB1 (0.49) | ABCB1BACE1HDAC1LMNAMAPT | |
| SCHEMBL1646634 | 0.82 | BACE1 (0.56) | BACE1ME2ME1ME3 | |
| SCHEMBL1646637 | 0.82 | BACE1 (0.56) | BACE1ME2ME1ME3 | |
| SCHEMBL1645641 | 0.82 | BACE1 (0.58) | BACE1 | |
| SCHEMBL1645644 | 0.82 | BACE1 (0.58) | BACE1 | |
| SCHEMBL3211891 | 0.82 | BACE1 (0.51) | ABCB1BACE1HDAC1 | |
| SCHEMBL3211881 | 0.82 | BACE1 (0.51) | ABCB1BACE1HDAC1 | |
| Hydrochloric Acid SCHEMBL1645748 | 0.80 | BACE1 (0.56) | ABCB1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | ABCB1 1952/4885BACE1 1/4885HDAC1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.